Drug intelligence / Profile preview

cannabidiolic acid methyl ester

Development stage: Preclinical
Lead developer: EPM
Modality: Small Molecules
Administration: Oral, Topical

Overview

Cannabidiolic acid methyl ester (EPM301) is a synthetic, stabilized derivative of cannabidiolic acid (CBDA) created through esterification. It was developed by Dr. Raphael Mechoulam to overcome the natural instability of CBDA. EPM301 has demonstrated potent anti-inflammatory, anti-obesity, and antidepressant properties in preclinical studies, showing efficacy comparable to steroids but with fewer side effects. It has shown promise for treating diet-induced obesity, Prader-Willi syndrome, inflammatory bowel disease, and inflammatory skin conditions.

Targets

LDLR (Low-density lipoprotein receptor)CNR1 (Cannabinoid receptor 1)PCSK9 (Proprotein convertase subtilisin/kexin type 9)

Beyond the preview

Go deeper on cannabidiolic acid methyl ester.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cannabidiolic acid methyl ester.

Explore the full profile